BIDMC researchers define immune system’s requirements for protection against COVID-19

Findings are important for vaccines, therapeutics and public health strategies to combat the COVID-19 pandemic

BOSTON – Since the novel coronavirus emerged at the end of last year, scientists around the world — including Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan Barouch, MD, PhD — have been developing vaccines to protect against COVID-19 and to put an end to the global pandemic. As of November 2020, three pharmaceutical companies released early data showing high rates of protection in Phase 3 human trials for their vaccines, but questions remain about how the body develops and maintains immunity after vaccination or infection.

In a new paper in the journal Nature, Barouch, Director of BIDMC's Center for Virology and Vaccine Research, and colleagues shed light on the role of antibodies and immune cells in protection against SARS-CoV-2, the virus that causes COVID-19, in rhesus macaques. "In this study, we define the role of antibodies versus T cells in protection against COVID-19 in monkeys. We report that a relatively low antibody titer (the concentration of antibodies in the blood) is needed for protection," said Barouch. "Such knowledge will be important in the development of next generation vaccines, antibody-based therapeutics, and public health strategies for COVID-19."

Building on previous findings that SARS-CoV-2 infection protects rhesus monkeys from re-exposure, Barouch and colleagues purified and collected antibodies from animals that had recovered from infection. They administered the antibodies at various concentrations to 12 uninfected macaques and observed that protection against SARS-CoV-2 challenge was dose dependent. Animals that received higher amounts of antibodies were protected more completely, while animals that received lower amounts of antibodies were protected less well. Similarly, when the researchers administered various concentrations of the purified antibodies to 6 macaques with active SARS-CoV-2 infection, those given higher doses demonstrated more rapid viral control.

In a second set of experiments, Barouch and colleagues evaluated the role of specific immune cells — CD8+ T cells — in contributing to protection against the virus by removing these cells from animals that had recovered from SARS-CoV-2 infection. Removal of these immune cells left the animals vulnerable to infection after re-exposure to SARS-CoV-2.

"Our data define the role of antibodies and T cells in protection against COVID-19 in monkeys. Antibodies alone can protect, including at relatively low levels, but T cells are also helpful if antibody levels are insufficient," said Barouch, who is also Professor of Medicine at Harvard Medical School, and a member of the Ragon Institute of MGH, MIT, and Harvard. ";Such correlates of protection are important given the recent successful vaccine results from human trials, and the likelihood that these and other vaccines will become widely available in the spring; as a result future vaccines may need to be licensed based on immune correlates rather than clinical efficacy."

Co-authors include co-first author Katherine McMahan, co-first author Jingyou Yu, co-first author Noe B. Mercado, co-first author Lisa H. Tostanoski, co-first author Abishek Chandrashekar, co-first author Jinyan Liu , co-first author Lauren Peter, Esther A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Catherine Jacob-Dolan, Zhenfeng Li, Felix Nampanya, and Shivani Patel of BIDMC; co-first author Carolin Loos, Caroline Atyeo, Alex Zhu, and Galit Alter, of Ragon Institute of MGH, MIT, and Harvard; Laurent Pessaint, Alex Van Ry, Kelvin Blade, Jake Yalley-Ogunro, Mehtap Cabus, Renita Brown, Anthony Cook, Elyse Teow, Hanne Andersen, Mark G. Lewis, of Bioqual; and Douglas A. Lauffenburger of Massachusetts Institute of Technology.

This work was supported by the Ragon Institute of MGH, MIT, and Harvard, Mark and Lisa Schwartz Foundation, Massachusetts Consortium on Pathogen Readiness (MassCPR), the Bill & Melinda Gates Foundation (INV-006131), and the National Institutes of Health (OD024917, AI129797, AI124377, AI128751, AI126603, CA260476).

The authors declare no financial conflicts of interest. Barouch is a co-inventor on provisional SARS-CoV-2 vaccine patents (62/969,008; 62/994,630).